A Phase 2 interventional study of Rimegepant and Placebo in Migraine and Acute Treatment of Migraine, sponsored by Pfizer. Completed at 41 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-02-28.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.
Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 9th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 2, and was the 1st registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States, Israel
Ages 18+
Pfizer · Sites in India
Ages 18+
Pfizer · Sites in United States, Israel
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 16 · Phase 4 9
First in 2011; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,026 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 618 across the 32 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 13th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2011, is the only one in phase 2, and was the 2nd registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing rimegepant in Migraine Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07918053Chinese PLA General HospitalA Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals | 2027-06 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing rimegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain") at 2 hours post dose using a four point numeric rating scale (no pain, mild pain, moderate pain, severe pain) while identifying an optimal dose to support the Phase 3 clinical trials.
Intervention Model: Parallel Versus Comparator + Placebo
Key Inclusion Criteria:
Patient with at least 1-year history of migraines (with or without aura) including the following:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose (one capsule) of rimegepant 10 milligram (mg) orally and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
Drug: Rimegepant · Drug: Placebo
Participants received a single dose (one capsule) of rimegepant 25 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
Drug: Rimegepant · Drug: Placebo
Participants received a single dose (one capsule) of rimegepant 75 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
Drug: Rimegepant · Drug: Placebo
Participants received a single dose (one capsule) of rimegepant 150 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
Drug: Rimegepant · Drug: Placebo
Participants received a single dose (two 150 mg capsules) of rimegepant 300 mg orally; and two rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
Drug: Rimegepant · Drug: Placebo
Participants received a single dose (four capsules of 150 mg each) of rimegepant 600 mg orally; anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
Drug: Rimegepant · Drug: Placebo
Participants received a single dose (4 capsules) of rimegepant placebo-matching capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
Drug: Placebo
Participants received a single dose (one capsule) of rimegepant-matching sumatriptan 100 mg orally and three rimegepant matching placebo capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
Drug: Placebo · Drug: Sumatriptan
Rimegepant capsules
Rimegepant placebo-matching capsules
Rimegepant matching sumatriptan and Rimegepant matching placebo capsules
Also known as: Imitrex®
Number of Pain Free Participants (Pain Freedom) at 2 Hours Post-dose
Pain freedom was defined as participants reporting a value of "none" on the four-point numeric rating scale (none=0, mild =1, moderate =2, severe =3) from baseline. Participants with baseline moderate pain or severe pain were included in the analysis.
Time frame: Baseline, 2 hours post-dose
Number of Participants With Total Migraine Freedom at 2 Hours Post Dose
Total migraine freedom is defined as complete absence of migraine symptoms. A participant was positive for total migraine freedom at a particular time point if he/she reports the absence of: pain, nausea, photophobia, and phonophobia. This corresponds to reporting "none" on each of the four-point numeric rating scale (none =0, mild =1, moderate =2, severe =3) from baseline associated with these symptoms. Participants with baseline moderate pain or severe pain were included in the analysis.
Time frame: Baseline, 2 hours post dose
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuation Due to Adverse Events
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition, unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or suspected transmission of an infectious agent, or encompassed any other clinically significant event that could jeopardize the subject or require medical or surgical intervention to prevent one of the aforementioned outcomes.
Time frame: AEs: from first dose to end of treatment visit (up to 7 weeks); SAE: from signing of informed consent to 30 days after the last dose (up to 11 weeks).
Number of Participants Achieving Sustained Pain Freedom From 2 to 24 Hours Post Dose
Participants were considered to have sustained pain freedom if all of their reported pain readings in the interval are "none" on the four point numeric rating scale (no pain=0, mild pain=1, moderate pain=2, severe pain=3). The intervals are inclusive of the endpoints. Sustained pain freedom was analyzed with a Cochran Mantel Haenszel (CMH) test for general association that compares the ED90 to placebo, and controls for baseline pain severity.
Time frame: 2 hours to 24 hours post dose
Number of Participants Achieving Sustained Pain Freedom From 2 to 48 Hours Post Dose
Participants were considered to have sustained pain freedom if all of their reported pain readings in the interval are "none" on the four point numeric rating scale (no pain=0, mild pain=1, moderate pain=2, severe pain=3). The intervals are inclusive of the endpoints. Sustained pain freedom was analyzed with a CMH test for general association that compares the ED90 to placebo, and controls for baseline pain severity.
Time frame: 2 hours to 48 hours post dose
The study was conducted at 41 centers in the United States. A total of 1026 participants were enrolled in the study, and 885 of these were randomized to treatment. Of the 141 participants who were not randomized, the main reason for non-randomization was participants no longer met inclusion criteria.
| Milestone | Treatment A: Rimegepant, 10 mg | Treatment B: Rimegepant, 25 mg | Treatment C: Rimegepant, 75 mg | Treatment D: Rimegepant, 150 mg | Treatment E: Rimegepant, 300 mg | Treatment F: Rimegepant, 600 mg | Treatment P: Rimegepant Placebo-Matching Capsules | Treatment G: Sumatriptan 100 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 85 | 68 | 91 | 90 | 121 | 92 | 229 | 109 |
| Completed | 72 | 62 | 86 | 86 | 112 | 84 | 210 | 100 |
| Not completed | 13 | 6 | 5 | 4 | 9 | 8 | 19 | 9 |
| Withdrew: Subject withdrew consent | 3 | 0 | 1 | 0 | 2 | 1 | 5 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 | 2 | 2 | 1 | 5 | 1 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Patient no longer meets study criteria | 7 | 6 | 3 | 2 | 5 | 5 | 9 | 6 |
Pain freedom was defined as participants reporting a value of "none" on the four-point numeric rating scale (none=0, mild =1, moderate =2, severe =3) from baseline. Participants with baseline moderate pain or severe pain were included in the analysis.
| Participants | Treatment A: Rimegepant, 10 mg | Treatment B: Rimegepant, 25 mg | Treatment C: Rimegepant, 75 mg | Treatment D: Rimegepant, 150 mg | Treatment E: Rimegepant, 300 mg | Treatment F: Rimegepant, 600 mg | Treatment P: Rimegepant Placebo-Matching Capsules | Treatment G: Sumatriptan 100 mg |
|---|---|---|---|---|---|---|---|---|
| Number of Pain Free Participants (Pain Freedom) at 2 Hours Post-dose | 14 | 12 | 27 | 28 | 33 | 20 | 31 | 35 |
Total migraine freedom is defined as complete absence of migraine symptoms. A participant was positive for total migraine freedom at a particular time point if he/she reports the absence of: pain, nausea, photophobia, and phonophobia. This corresponds to reporting "none" on each of the four-point numeric rating scale (none =0, mild =1, moderate =2, severe =3) from baseline associated with these symptoms. Participants with baseline moderate pain or severe pain were included in the analysis.
| Participants | Treatment A: Rimegepant, 10 mg | Treatment B: Rimegepant, 25 mg | Treatment C: Rimegepant, 75 mg | Treatment D: Rimegepant, 150 mg | Treatment E: Rimegepant, 300 mg | Treatment F: Rimegepant, 600 mg | Treatment P: Rimegepant Placebo-Matching Capsules | Treatment G: Sumatriptan 100 mg |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Total Migraine Freedom at 2 Hours Post Dose | 13 | 11 | 24 | 22 | 26 | 16 | 24 | 32 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition, unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or suspected transmission of an infectious agent, or encompassed any other clinically significant event that could jeopardize the subject or require medical or surgical intervention to prevent one of the aforementioned outcomes.
| Participants | Treatment A: Rimegepant, 10 mg | Treatment B: Rimegepant, 25 mg | Treatment C: Rimegepant, 75 mg | Treatment D: Rimegepant, 150 mg | Treatment E: Rimegepant, 300 mg | Treatment F: Rimegepant, 600 mg | Treatment P: Rimegepant Placebo-Matching Capsules | Treatment G: Sumatriptan 100 mg |
|---|---|---|---|---|---|---|---|---|
| AEs | 15 | 10 | 18 | 12 | 18 | 14 | 29 | 17 |
| SAEs | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Participants discontinued due to AEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Participants were considered to have sustained pain freedom if all of their reported pain readings in the interval are "none" on the four point numeric rating scale (no pain=0, mild pain=1, moderate pain=2, severe pain=3). The intervals are inclusive of the endpoints. Sustained pain freedom was analyzed with a Cochran Mantel Haenszel (CMH) test for general association that compares the ED90 to placebo, and controls for baseline pain severity.
| Participants | Treatment A: Rimegepant, 10 mg | Treatment B: Rimegepant, 25 mg | Treatment C: Rimegepant, 75 mg | Treatment D: Rimegepant, 150 mg | Treatment E: Rimegepant, 300 mg | Treatment F: Rimegepant, 600 mg | Treatment P: Rimegepant Placebo-Matching Capsules | Treatment G: Sumatriptan 100 mg |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Achieving Sustained Pain Freedom From 2 to 24 Hours Post Dose | 9 | 10 | 24 | 24 | 29 | 17 | 15 | 26 |
Participants were considered to have sustained pain freedom if all of their reported pain readings in the interval are "none" on the four point numeric rating scale (no pain=0, mild pain=1, moderate pain=2, severe pain=3). The intervals are inclusive of the endpoints. Sustained pain freedom was analyzed with a CMH test for general association that compares the ED90 to placebo, and controls for baseline pain severity.
| Participants | Treatment A: Rimegepant, 10 mg | Treatment B: Rimegepant, 25 mg | Treatment C: Rimegepant, 75 mg | Treatment D: Rimegepant, 150 mg | Treatment E: Rimegepant, 300 mg | Treatment F: Rimegepant, 600 mg | Treatment P: Rimegepant Placebo-Matching Capsules | Treatment G: Sumatriptan 100 mg |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Achieving Sustained Pain Freedom From 2 to 48 Hours Post Dose | 8 | 9 | 24 | 24 | 29 | 17 | 15 | 26 |
Collected over AEs: from first dose to end of treatment visit (up to 52 days); SAE: from signing of informed consent to 30 days after the last dose (up to 80 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: Rimegepant, 10 mg | 0/85 (0%) | 0/72 (0%) | 4/72 (5.6%) |
| Treatment B: Rimegepant, 25 mg | 0/68 (0%) | 0/62 (0%) | 0/62 (0%) |
| Treatment C: Rimegepant, 75 mg | 0/91 (0%) | 0/86 (0%) | 3/86 (3.5%) |
| Treatment D: Rimegepant, 150 mg | 0/90 (0%) | 3/86 (3.5%) | 3/86 (3.5%) |
| Treatment E: Rimegepant, 300 mg | 0/121 (0%) | 0/112 (0%) | 6/112 (5.4%) |
| Treatment F: Rimegepant, 600 mg | 0/92 (0%) | 0/84 (0%) | 7/84 (8.3%) |
| Treatment P: Rimegepant Placebo-Matching Capsules | 0/229 (0%) | 0/209 (0%) | 5/209 (2.4%) |
| Treatment G: Sumatriptan 100 mg | 0/109 (0%) | 0/100 (0%) | 2/100 (2%) |
| Event | Treatment A: Rimegepant, 10 mg | Treatment B: Rimegepant, 25 mg | Treatment C: Rimegepant, 75 mg | Treatment D: Rimegepant, 150 mg | Treatment E: Rimegepant, 300 mg | Treatment F: Rimegepant, 600 mg | Treatment P: Rimegepant Placebo-Matching Capsules | Treatment G: Sumatriptan 100 mg |
|---|---|---|---|---|---|---|---|---|
| PNEUMONIAInfections and infestations | 0/72 | 0/62 | 0/86 | 1/86 | 0/112 | 0/84 | 0/209 | 0/100 |
| POST LUMBAR PUNCTURE SYNDROMEInjury, poisoning and procedural complications | 0/72 | 0/62 | 0/86 | 1/86 | 0/112 | 0/84 | 0/209 | 0/100 |
| STRESS CARDIOMYOPATHYCardiac disorders | 0/72 | 0/62 | 0/86 | 1/86 | 0/112 | 0/84 | 0/209 | 0/100 |
| Event | Treatment A: Rimegepant, 10 mg | Treatment B: Rimegepant, 25 mg | Treatment C: Rimegepant, 75 mg | Treatment D: Rimegepant, 150 mg | Treatment E: Rimegepant, 300 mg | Treatment F: Rimegepant, 600 mg | Treatment P: Rimegepant Placebo-Matching Capsules | Treatment G: Sumatriptan 100 mg |
|---|---|---|---|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 1/72 | 0/62 | 3/86 | 3/86 | 5/112 | 7/84 | 5/209 | 2/100 |
| DIARRHOEAGastrointestinal disorders | 4/72 | 0/62 | 0/86 | 0/86 | 1/112 | 0/84 | 0/209 | 0/100 |
The analysis was performed in randomized population defined as all participants who were randomized to double-blind treatment.
| Age, Continuous(years) | Treatment A: Rimegepant, 10 mg | Treatment B: Rimegepant, 25 mg | Treatment C: Rimegepant, 75 mg | Treatment D: Rimegepant, 150 mg | Treatment E: Rimegepant, 300 mg | Treatment F: Rimegepant, 600 mg | Treatment P: Rimegepant Placebo-Matching Capsules | Treatment G: Sumatriptan 100 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 41.1 ± 10.36 | 36.5 ± 11.92 | 38.5 ± 11.87 | 39.2 ± 11.26 | 41.9 ± 11.46 | 39.3 ± 13.01 | 37.9 ± 11.36 | 40.6 ± 10.47 | 39.3 ± 11.52 |
| Sex: Female, Male(Participants) | Treatment A: Rimegepant, 10 mg | Treatment B: Rimegepant, 25 mg | Treatment C: Rimegepant, 75 mg | Treatment D: Rimegepant, 150 mg | Treatment E: Rimegepant, 300 mg | Treatment F: Rimegepant, 600 mg | Treatment P: Rimegepant Placebo-Matching Capsules | Treatment G: Sumatriptan 100 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 67 | 61 | 81 | 63 | 101 | 76 | 196 | 91 | 736 |
| Male | 18 | 7 | 10 | 27 | 20 | 16 | 33 | 18 | 149 |
Ran from Oct 2011 to primary completion in May 2012, 7 months.
Results were first posted in Sep 2020, 8 years 4 months after primary completion. A results delay was requested in Sep 2015.
Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 7 months is below that.
Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimegepant